Controlling Viral Infection With Metadichol | 51618
Journal of Infectious Diseases & Therapy
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Metadichol (US patent 8,722,093) is a nano-emulsion of long-chain alcohols found in many foods. It is commonly called
Policosanol and is present in foods such as rice, sugar cane, wheat, peanuts. Metadichol acts on Nuclear Vitamin D
receptors (VDR) (US patent 9,006,292) that are present in cells throughout the body to stimulate the immune system and
inhibit a variety of disease processes, resulting from viral infections. We tested for antiviral activity of Metadichol® in Vero and
MDCK cells infected with Influenza A, H1N1, Human Respiratory Syncytial virus, Dengue, Chikungunya and Ebola, Marburg.
In addition, we tested the efficacy of Metadichol® in preventing cell death caused by Adenovirus, Tacaribe Mammarena virus,
Rift Valley Fever virus, SARS coronavirus, Japanese Encephalitis virus, West Nile virus, and Yellow Fever virus. In the in vitro
assays, Metadichol showed no cytotoxicity and strongly inhibited cell death caused by each of the viruses tested. Metadichol
is a safe and effective inhibitor of enveloped viruses in humans. Since it is known to bind to the vitamin D receptor (VDR)
(US patent 9,006,292), its mechanism of action likely involves the competitive displacement of virus particles from VDR’s on
host cell membranes. Because it consists of natural components of common foods and has no known negative side effects,
Metadichol has the potential to serve as a novel, broad-spectrum antiviral treatment for Dengue, Ebola, Zika, H1N1, SARS,
Chikungunya and other enveloped viruses.
Palayakotai Raghavan is the CEO and Founder of Nanorx Inc., New York, USA. He has completed his PhD in Organic Chemistry from Oregon State University in 1979 and MS in Chemistry in 1972 from IIT Mumbai, India. He has worked on drug discovery for over 25 years at Columbia University, Max-Planck Institute, Germany, Ciba-Geigy (now Novartis) and Boehringer Ingelheim. He has over 12 patents and another 15 pending patent applications.